GET DAILY SIGNALSWhy Is Axon Enterprise (AXON) Stock Down -17.67% Today?
Key Takeaways
- AXON shares plunged 17.67% to roughly $314.95, extending a steep post-earnings selloff.
- The primary catalyst was a third-quarter revenue and earnings miss, coupled with a cut to full-year revenue guidance.
- Management blamed roughly $130 million in delayed federal Dedrone (counter-drone) deployments for the softer outlook.
- Margin pressure from higher memory costs and a $1.2 billion investment in drone maker Skydio added to investor concerns.
- Several Wall Street analysts lowered their price targets in response to the results.
- Traders are now watching fourth-quarter execution, federal procurement timing, and whether the delayed deals land in 2027.
- For deeper context, explore Price Targets, Earnings, and Forecast data on additional pages.
- You can also discover top-performing AI trading strategies on the Trending AI Robots page.
Opening Summary
Axon Enterprise, Inc. (AXON) — the Scottsdale, Arizona-based public safety technology company known for TASER conducted energy weapons, body cameras, and the Axon Cloud software platform — suffered a sharp decline in Friday's session, falling 17.67% to about $314.95 from a prior close of $382.56. The move marked a dramatic extension of Thursday's after-hours drop, which was triggered by weaker-than-expected third-quarter results and reduced full-year revenue guidance. The core issue cited by markets was the timing of large federal counter-drone deployments, which pushed roughly $130 million of expected revenue out of 2026.
Earnings Miss and Guidance Cut
The selloff traces directly to AXON's third-quarter report. Revenue rose 28% year over year to a record $908.55 million, but that figure missed consensus estimates of roughly $937 million. Non-GAAP earnings per share came in at $1.72, below the approximately $1.88 to $1.91 analysts had projected. More damaging was the outlook: management lowered full-year revenue guidance to a range of $3.61 billion to $3.63 billion, implying about 30% growth, down from the prior 32% to 34% range. The company also guided fourth-quarter revenue to $990 million to $1.01 billion, below the roughly $1.06 billion Wall Street expected.
Delayed Federal Drone Deployments
At the center of the guidance revision were three large federal Dedrone counter-drone deployments totaling about $130 million in revenue that are no longer expected to close within 2026. Company leadership attributed the slippage to slower federal procurement, election-cycle dynamics, and the complex logistics — including ITAR permitting and acceptance testing — involved in hardware-heavy deployments. Executives emphasized that demand remains strong and characterized the shortfall as a timing issue rather than lost business, but the market's reaction reflected concern about increased quarter-to-quarter volatility in the counter-drone business.
Skydio Investment and Margin Pressure
Compounding the reaction, AXON announced a $1.2 billion investment in drone maker Skydio, lifting its ownership stake to 37% and making it Skydio's exclusive public-safety distributor in the U.S. and Canada. While management framed the deal as a strategic bet on the "Drone as First Responder" market, investors weighed the capital outlay against already pressured fundamentals. Gross margin declined to 56.7% from 60.1% a year earlier, hurt by a higher mix of counter-drone hardware and elevated memory costs, and the company also trimmed its free cash flow guidance to $350 million–$400 million from $450 million due to accelerated inventory investment.
Analyst Reaction
The miss prompted a wave of downward price-target revisions. Needham lowered its target from $750 to $500 while maintaining a Buy rating, Piper Sandler trimmed its target from $561 to $540, and Barclays cut its target from $688 to $507. The negative revisions underscored how quickly sentiment can shift for a stock that had been trading at a premium growth multiple, and they added selling pressure on top of the fundamental disappointment.
Market Context and Trading Activity
Trading volume was exceptionally heavy, with millions of shares changing hands versus a 30-day average of roughly one million, reflecting intense repositioning. The decline also stood in contrast to rival Motorola Solutions (MSI), which had raised its own outlook earlier in the week, and to memory supplier Micron Technology, whose results have benefited from the same cost dynamics now squeezing AXON's hardware margins. The move pushed the stock well below recent support levels and deeper into a technical breakdown that began Thursday.
What Comes Next for AXON
Looking ahead, investors will focus on whether the delayed federal deployments materialize in early 2027, which would effectively shift roughly $130 million of revenue into next year. Key watch items include fourth-quarter execution, the pace of Software & Services growth (which accelerated 43% and now contributes $437 million), AI annual recurring revenue, which surpassed $100 million, and the trajectory of memory costs on margins. Risks include further procurement delays, margin compression, and the integration and capital demands of the expanded Skydio partnership. No single catalyst guarantees a rebound, and near-term volatility is likely to persist.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies varying by approach, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this section, making it a useful starting point for traders seeking automated, data-driven strategies. Explore the Trending AI Robots page to see which strategies are leading today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXON sees MACD Histogram just turned negative
AXON saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 32 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AXON's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (4.822). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.059). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.057) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement